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http:WHAT THIS PAPER ADDS
There are few data regarding risk assessment in revascularization for critical limb ischaemia, because few
validation studies have been published regarding the established risk scores (Finnvasc and PREVENT III). A new
risk model has been developed and validated in the clinical setting by comparing it with other established
models. This model is offered to the vascular community to encourage its external validation in other clinical
environments in order to advance the objective assessment of surgical risk in these patients.Objectives: It is difﬁcult to establish which patients suffering from critical lower limb ischaemia will beneﬁt from
revascularization. Risk scores can provide objectivity in decision making. The aim was to design a new risk score
(ERICVA) and compare its predictive power with the PREVENT III and Finnvasc scores.
Methods: An observational retrospective study of patients who underwent revascularization (open or
endovascular) in Valladolid’s University Hospital between 2005 and 2010 was designed. The sample was divided
into two subgroups (development and validation subsamples). After univariate analysis followed by a
multivariate Cox regression, a number of variables associated with death and/or major amputation were
selected, creating a weighed score called ERICVA, and a simpliﬁed version of it. The area under the curve (AUC) of
receiver operating characteristic (ROC) curve analysis was performed and the AUC of these two scores were
additionally compared with the AUC of the PREVENT III and Finnvasc scales.
Results: Six hundred and seventy two cases with an average surveillance of 778 days were included in the study.
Amputation free survival (AFS) was 84.8% at 30 days and 63.1% at 1 year. Variables associated with death and/or
major amputation in the Cox regression were cerebrovascular disease, prior contralateral major amputation,
diabetes mellitus, dialysis, chronic obstructive pulmonary disease, cancer, haematocrit less than 30%, neutrophil/
lymphocyte ratio exceeding 5, absence of arterial Doppler signal at the ankle, emergency admission, and
Rutherford stage 6; these variables were used for the ERICVA and simpliﬁed ERICVA score designs. Scores were
applied to both subsamples; in the development sample the AUC of ERICVA and simpliﬁed ERICVA was
signiﬁcantly higher than the PREVENT III (p ¼ .008 and p ¼ .045) and Finnvasc (p < .0001 and p ¼ .0013) scores;
in the validation sample the AUC of ERICVA and simpliﬁed ERICVA were signiﬁcantly higher than Finnvasc score
(p ¼ .0323 and p ¼ .0017).
Conclusions: The ERICVA model has a good predictive capacity for death and/or major amputation in the clinical
setting, and is better than the PREVENT III and Finnvasc scores.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2015.09.025of comorbidity, and it is associated with a high risk of death
and/or major amputation of the extremity.1 The treatment
of choice is revascularization when technically possible, but
not all patients can beneﬁt from it; many patients are too
fragile to withstand the intervention and, in many of them,
the risk beneﬁt ratio is unfavourable. Published series show
that despite revascularization, the rate of death and major
amputation in the short and medium term remains high.2
Furthermore, it is often difﬁcult to decide which patients
will beneﬁt from intervention, as the speciﬁc weights of
several markers of risk are not clearly established.
Figure 1. Study ﬂowchart.
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world of surgery as an objective tool for assessing the risk of
intervention beyond traditional clinical judgment, which is
not without subjective inﬂuences.3 An example of this is the
successful and extensively used Euroscore in cardiac sur-
gery.4 However, in vascular surgery in general (and critical
ischaemia in particular), this is an area that is yet to be
developed. So far, four predictive risk models have been
published for revascularization for CLI.
The Finnvasc risk scale (derived from the Finnish vascular
registry) was developed with the aim of predictingTable 1. Descriptive analysis of the results of the intervention in t
“Validation” subsamples (*, p < 0.05).
Total sample
(n ¼ 672) n (%
Major amputation (30 days) 64 (9.5)
Major amputation (1 year) 149 (22.2)
Death (30 days) 41 (6.1)
Death (1 year) 102 (15.2)
AFS (30 days) 570 (84.8)
AFS (1 year) 424 (63.1)
Cardiac complications (30 days) 58 (8.6)
Pulmonary complications (30 days) 51 (7.6)
Neurological complications (30 days) 7 (1)
Haemodialysis due to post-operative acute renal
failure (30 days)
2 (0.3)
Surgical wound/puncture area related
complications (30 days)
87 (12.9)
Minor secondary amputation (30 days) 101 (15)
Other major complications (30 days) 16 (2.4)
AFS ¼ amputation free survival.amputation free survival (AFS) over 30 days in patients
undergoing conventional infrainguinal revascularization
surgery.5 The PREVENT III risk scale (derived from a clinical
trial with the same name) was designed to predict AFS 1
year after autologous infrainguinal bypass.6 The BASIL risk
model was established with the aim of predicting the
probability of survival (regardless of the risk of amputation)
2 years after revascularization.7 Finally, the CRAB risk model
was developed to predict mortality and major morbidity at
30 days (regardless of the risk of amputation) in patients
undergoing infrainguinal bypass.8he sample and comparison between “Score development” and
)
Score development
subsample
(n ¼ 561) n (%)
Validation subsample
(n ¼ 111) n (%)
p
57 (10.2) 7 (6.4) .224
127 (22.6) 22 (920.2) .573
36 (6.5) 5 (994.7) .464
88 (15.6) 27 (24.6) .032*
475 (84.6) 100 (89.9) .168
357 (63.6) 68 (61.1) .631
48 (8.6) 10 (9) .877
40 (7.1) 11 (9.9) .312
5 (0.9) 2 (1.8) .388
2 (0.4) 0 (0) .529
76 (13.5) 11 (9.9) .297
83 (14.8) 18 (16.2) .702
13 (2.3) 3 (2.7) .808
Table 2. Descriptive analysis of pre-operative variables in the complete sample, in the “development” and “validation” groups, and
comparison between subgroups (*, p < 0.05).
Total sample
(n ¼ 672) n (%)
Score development
subsample
(n ¼ 561) n (%)
Validation subsample
(n ¼ 111) n (%)
p
Sex (males) 558 (83) 467 (83.2) 91 (82) .746
Age (years, mean  SD) 72.41  10.7 72.19  10.73 73.50  10.47 .240
Urgent admission 479 (71.3) 403 (71.8) 76 (68.5) .474
Rutherford class .518
6 275 (40.9) 235 (41.9) 40 (36)
5 297 (44.2) 244 (43.5) 53 (47.7)
4 100 (14.9) 82(14.6) 18 (16.2)
Ankle Doppler signal .425
Biphasic waveform 290 (43.2) 239 (42.6) 51 (45.9)
Monophasic waveform 217 (32.3) 187 (33.3) 30 (27)
Absent of arterial signal 165 (24.6) 135 (24.1) 30 (27)
Vessel calciﬁcation (ankle brachial index >1.3) 172 (25.6) 134 (23.9) 38 (34.2) .022*
Vascular risk factors, comorbidity, and medication
Hypertension 431 (64.1) 354 (63.1) 77 (69.4) .208
Diabetes mellitus 331 (49.3) 269 (48) 62 (55.9) .128
Dyslipidaemia 270 (40.2) 208 (37.1) 62 (55.9) <.001*
Smoker 434 (64.6) 362 (64.5) 72 (64.9) .946
Cerebrovascular disease 81 (12.1) 67 (11.9) 14 (12.6) .843
Ischaemic heart disease 172 (25.6) 131 (23.4) 41 (36.9) .003*
Chronic heart failure 88 (13.1) 71 (12.7) 17 (15.3) .448
COPD/asthma 104 (15.5) 86 (15.3) 18 (16.2) .813
Chronic renal failure 94 (14) 77 (13.7) 17 (15.3) .659
Dialysis 23 (3.4) 19 (3.4) 4 (3.6) .909
Cancer 71 (10.6) 58 (10.3) 13 (11.7) .667
Antiplatelet treatment 445 (66.2) 364 (64.9) 81 (73) .100
Anticoagulation 89 (13.2) 73 (13) 16 (14.4) .691
Statins 246 (36.6) 182 (32.4) 64 (57.7) <.001*
Beta blockers 107 (15.9) 83 (14.8) 24 (21.6) .072
Previous contralateral major amputation 55 (8.2) 42 (7.5) 13 (11.7) .138
Previous contralateral revascularization 177 (26.3) 149 (26.6) 28 (25.2) .771
Previous major revascularization (same limb) 186 (27.7) 149 (26.6) 37 (33.3) .145
Pre-operative blood tests (mean  SD)
Haemoglobin (mg/L) 12.84  2.18 12.89  2.18 12.58  2.18 .179
Haematocrit (%) 38.76  6.02 38.98  6.03 37.93  5.84 .032*
Leucocytes ( 109/L) 8.5  3.07 8.45  3.09 8.80  2.96 .268
Neutrophils ( 109/L 5.81  2.79 5.73  2.77 6.21  2.87 .94
Lymphocytes ( 109/L) 1.88  1.07 1.90  1.12 1.77  0.81 .236
Neutrophil/lymphocyte ratio 3.9  3.29 3.78  3.16 4.5  3.83 .037*
Platelets ( 109/L) 246.1  93.53 247.94  96 236.83  79.7 .254
Urea (mg/dL) 55.08  30.43 54.86  30.54 56.21  29.96 .671
Creatinine (mg/dL) 1.35  1.24 1.34  1.22 1.41  1.34 .578
Glucose (mg/dL) 118.9  54.52 116.80  53.18 129.49  60.01 .025*
Sodium (mEq/L) 138.26  4.41 138.38  4.54 137.68  3.57 .130
Potassium (mEq/L) 4.43  0.57 4.44  0.58 4.37  0.54 .200
Osmolarity (mOsm/L) 290.04  14.08 289.89  14.56 290.65  11.8 .631
Total proteins (g/dL) 6.7  0.75 6.73  0.74 6.49  0.76 .003*
Albumin (g/dL) 3.64  0.55 3.65  0.56 3.60  0.48 .266
Planned intervention
Aorto-iliac surgery 57 (8.5) 54 (9.6) 3 (2.7) .017*
Extra-anatomic aorto-iliac surgery 40 (6) 36 (6.4) 4 (3.6) .252
Femoral endarterectomy (common/deep
femoral arteries)
133 (19.8) 113 (20.1) 20 (18) .608
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Table 2-continued
Total sample
(n ¼ 672) n (%)
Score development
subsample
(n ¼ 561) n (%)
Validation subsample
(n ¼ 111) n (%)
p
Autologous above knee femoro-popliteal
bypass
10 (1.5) 6 (1.1) 4 (3.6) .044*
Prosthetic above knee femoro-popliteal bypass 111 (16.5) 95 (16.9) 16 (14.4) .514
Prosthetic below knee femoro-popliteal bypass 20 (3) 16 (2.9) 4 (3.6) .670
Autologous below knee femoro-popliteal
bypass
133 (19.8) 119 (21.2) 14 (12.6) .038*
Distal (infra-popliteal) bypass 77 (11.5) 62 (11.1) 15 (13.5) .457
Aorto-iliac endovascular surgery 106 (15.8) 88 (15.7) 18 (16.2) .889
Femoro-popliteal endovascular surgery 122 (18.2) 96 (17.1) 26 (23.4) .115
Distal endovascular surgery 64 (9.5) 37 (6.6) 27 (24.3) <.001*
Primary minor amputation 161 (24) 128 (22.8) 33 (29.7) .119
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these scales,9e12 their use in clinical practice is scarce, and
there are few reliable data regarding their applicability to
different populations other than those on which they were
developed.
Objective
The aim of this work was to create a new risk model to
predict the risk of death and/or major amputation at 1 year
in patients operated on for CLI from the patients in the local
area and population, and to compare it with the PREVENT III
and Finnvasc scales. The risk model designed was named
ERICVA (Escala de Riesgo en Isquemia Crítica de Valladolid,
Valladolid Critical Limb Ischaemia Risk Scale).
MATERIALS AND METHODS
Overview
An observational retrospective study of patients operated
on for critical ischaemia of the lower limb at Valladolid’s
University Hospital was designed. The main endpoint in the
study was the AFS 1 year after the procedure.
All revascularized patients diagnosed with critical
ischaemia (Rutherford stages 4, 5, or 6) between January 1,
2005, and June 30, 2010, were included (conventional or
endovascular treatment). Cases of critical ischaemia of non-
atherosclerotic aetiology (embolic, traumatic, or vasculitic),
patients who did not survive the ﬁrst 24 hours after inter-
vention, and those cases in which primary major amputa-
tion was performed without a previous revascularization
procedure, were excluded.
In each patient, age, sex, clinical stage at admission,
vascular physical examination, haemodynamic examination
(Doppler), vascular risk factors, medication, comorbidity,
previous surgery for lower extremity ischaemia, procedure
performed, blood tests, 30 day post-operative complica-
tions, need for major ipsilateral amputation, and death
were registered.
The information was gathered from the intervention
sheet ﬁled in the hospital and medical records (paper or
digital) of each patient, creating a standardized data sheet
for later registration in a computer database. The status ofeach patient at follow up, in terms of survival and need for
major amputation was registered from the clinical history
data, by telephone contact and through inquiries in the Civil
Registry ofﬁces.
Flowchart of the study and statistics
First, a descriptive study of the total sample of patients was
performed. Subsequently, the sample was divided into two
groups: one for the development of the ERICVA scale (pa-
tients operated on between January 1, 2005, and December
31, 2009), and another for the validation of the scale (pa-
tients operated on between January 1, 2010, and June 30,
2010). Both groups were compared for any difference with
a Student t test for qualitative variables and a chi-square
test for quantitative variables (Fig. 1).
Using the development sample, a univariate Cox regres-
sion was conducted to ﬁnd variables associated with AFS;
continuous variables (laboratory parameters) were trans-
formed into discrete variables to perform this analysis
(transformation was done using normal laboratory values as
cut off points, as shown in Table 3).
The variables in the univariate analysis that reached a
signiﬁcance of p < .05 were included in a multivariate Cox
regression analysis (backward method) to determine which
ones were associated with statistical signiﬁcance for AFS.
From the variables selected in the Cox regression, the
ERICVA risk model was designed, creating an additive score.
The value of each item was ﬁxed by multiplying the beta
coefﬁcient (Cox regression) by 10 and was rounded to the
nearest whole number to facilitate summation. Subse-
quently, a simpliﬁed version of the ERICVA model was
designed with the ﬁve variables with higher speciﬁc weight
creating a sum in which each item added one point.
Subsequently, the Finnvasc, PREVENT III, ERICVA, and
ERICVA-Simpliﬁed scales were applied to both subsamples
to assess their predictive ability to detect AFS at 1 year.
Receiver operating characteristic curves for each of them
were calculated, comparing the area under the curve (AUC)
with the DeLong et al. method.13
All statistical analysis was performed with SPSS 17 (SPSS
Inc. Chicago, IL, USA), except AUC comparisons, which were
performedwith EPIDAT 3.1 (Xunta de Galicia, Spain) software.
Table 3. Univariate analysis using Cox regression (association between different pre-operative variables and amputation and/or death)
(*, p < 0.05).
Variable (association with death and/or major amputation) HR IC 95% p
Lower Upper
Sex (male/female) 1.004 0.722 1.397 .981
Age (over or under 75 years) 1.199 0.937 1.535 .148
Urgent admission 1.287 0.970 1.706 .043*
Rutherford class Overall <.001*
6 2.047 1.507 2.779 <.001*
5 0.907 0.709 1.159 .435
4 0.762 0.593 0.978 .033*
Peri-malleolar Doppler signal Overall .004
Biphasic 0.709 0.552 0.910 .007*
Monophasic 1.132 0.877 1.462 .341
Absent 1.356 1.033 1.779 .028*
Vessel calciﬁcation (ABI >1.3) 1.322 1.007 1.735 .043*
Vascular risk factors Hypertension 1.105 0.858 1.424 .437
Diabetes mellitus 1.279 1.003 1.630 .047*
Dyslipidaemia 0.704 0.542 0.914 .008*
Smoker 0.869 0.676 1.118 .274
Comorbidity Cerebrovascular disease 1.582 1.120 2.233 .009*
Ischaemic heart disease 1.172 0.885 1.552 .266
Chronic heart failure 1.768 1.273 2.456 <.001*
COPD/asthma 1.713 1.263 2.323 <.001*
Chronic renal failure 1.394 0.993 1.958 .049*
Dialysis 2.643 1.565 4.462 <.001*
Active cancer in previous 5 years 2.782 2.005 3.858 <.001*
Medication prior to surgery Antiplatelet medication 1.043 0.808 1.347 .744
Anticoagulant 1.134 0.801 1.606 .478
Statins 0.928 0.714 1.206 .577
Beta blockers 1.347 0.970 1.870 .074
Previous interventions for CLI Previous contralateral major amputation 1.560 1.024 2.375 .037*
Previous contralateral revascularization 1.369 1.055 1.777 .018*
Previous same limb revascularization 1.129 0.865 1.473 .372
Pre-operative blood tests Haemoglobin (<10 mg/L) 2.366 1.659 3.374 <.001*
Haematocrit (<30%) 2.613 1.761 3.878 <.001*
Leucocytes (>10  109/L) 1.458 1.105 1.923 .007*
Neutrophils (>7.5  109/L 1.686 1.275 2.229 <.001*
Lymphocytes (<1.5  109/L) 1.830 1.431 2.341 <.001*
Neutrophil/lymphocyte ratio (>5) 2.167 1.645 2.856 <.001*
Platelets (>450  109/L) 1.771 1.096 2.861 .018*
Urea (>40 mg/dL) 0.954 0.740 1.230 .716
Creatinine (>1.5 mg/dL) 1.111 0.821 1.503 .495
Glucose (>126 mg/dL) 1.285 0.986 1.673 .062
Sodium (<135 mEq/L) 1.414 1.042 1.918 .025*
Potassium (>5 mEq/L) 0.243 1.539 0.747 .286
Osmolarity (<280 mOsm/L) 1.131 0.855 1.495 .388
Total proteins (<6 g/dL) 0.719 0.504 1.026 .068
Albumin (<3 g/dL) 2.391 1.475 3.874 <.001*
Planned intervention Aorto-iliac surgery 0.724 0.471 1.111 .137
Extra-anatomic aorto-iliac surgery 0.944 0.569 1.566 .824
Femoral endarterectomy (common/deep
femoral)
0.847 0.616 1.165 .307
Autologous above knee femoro-popliteal bypass 1.334 0.427 4.167 .618
Prosthetic above knee femoro-popliteal bypass 1.091 0.801 1.485 .582
Prosthetic below knee femoro-popliteal bypass 2.261 1.234 4.141 .007*
Autologous below knee femoro-popliteal bypass 0.748 0.546 1.023 .068
Distal bypass 1.573 1.110 2.228 .010*
Aorto-iliac endovascular surgery 1.020 0.731 1.425 .906
Femoro-popliteal endovascular surgery 1.197 0.869 1.649 .269
Distal endovascular surgery 1.501 0.959 2.349 .074
Primary minor amputation 1.560 1.024 2.375 .013*
HR ¼ hazard ratio.
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Table 5. ERICVA Scale (development from the B coefﬁcient).
ERICVA risk scale B Coefﬁcient Value
Cerebrovascular disease 0.511 5 points
Previous contralateral
major amputation
0.452 5 points
Diabetes mellitus 0.259 3 points
Dialysis 0.919 9 points
COPD/asthma 0.564 6 points
Active cancer previous 5 years 1.180 12 points
Haematocrit <30% 0.912 9 points
Neutrophil/lymphocyte ratio >5 0.844 8 points
Absent peri-malleolar
Doppler signal
0.558 6 points
Urgent admission 0.299 3 points
Rutherford class
(major tissue loss)
0.865 9 points
Table 6. Simpliﬁed ERICVA Scale: the ﬁve items with the greatest
weight in ERICVA score were selected to create the simpliﬁed
version.
Simpliﬁed ERICVA risk scale Value
Dialysis 1 point
Active cancer previous 5 years 1 point
Haematocrit <30% 1 point
Neutrophil/lymphocyte ratio >5 1 point
Rutherford class 6 (major tissue loss) 1 point
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Descriptive analysis
A total of 672 cases with a mean follow up of 778 days were
included in the study; 561 cases were included in the sub-
group for the development of the ERICVA scale, and the
other 111 cases formed the subgroup used for validation
and comparison with the other two scales. The character-
istics of the sample and comparative analysis of both sub-
groups (which proved to be very similar) are shown in
Tables 1 and 2.
Univariate analysis
Table 3 shows the results of the univariate Cox regression
analysis that was applied to all pre-operative variables
regarding major AFS.
Multivariate analysis
The variables in the univariate analysis that were associated
with death and/or major amputation (p < .05) were
included in a multivariate model (Cox regression). In this
multivariate analysis, the variables that were statistically
signiﬁcant were cerebrovascular disease, previous contra-
lateral amputation, diabetes mellitus, dialysis, COPD/
asthma, active neoplasm in the previous 5 years, 30% or
lower haematocrit, neutrophil/lymphocyte ratio 5 or higher,
absence of arterial Doppler signal in the ankle, emergency
admission, and Rutherford stage 6 ischaemia (Table 4).
Design of ERICVA and simpliﬁed ERICVA scales
From the statistically signiﬁcant variables in the Cox
regression, the ERICVA scale was designed so that the beta-
coefﬁcient of each one was multiplied by 10 and rounded to
the nearest whole number, creating an additive scale in
which each variable sums a value which is directly propor-
tional to its association with death or major amputation
(Table 5).
To create a simpler version of the scale (which is called
ERICVA-Simpliﬁed), the ﬁve variables with greatest weight
were used to create a sum scale in which each item adds 1
point (Table 6).Table 4. Multivariate analysis using Cox regression.
Cox regression B Coefﬁcient p
Cerebrovascular disease 0.511
Previous contralateral major amputation 0.452
Diabetes mellitus 0.259
Dialysis 0.919
COPD/asthma 0.564 <
Active cancer previous 5 years 1.180 <
Haematocrit <30% 0.912 <
Neutrophil/lymphocyte ratio>5 0.844 <
Absent peri-malleolar Doppler signal 0.558 <
Urgent admission 0.299
Rutherford class 6 (major tissue loss) 0.865 <
COPD ¼ chronic obstructive pulmonary disease.After applying both scales to the development sample, it
was found that a higher score correlated with lower AFS.
For the ERICVA scale, the distribution of scores was divided
in tertiles to create different risk levels (Fig. 2); in this way
the ERICVA scale was divided into low (0e9 points), me-
dium (10e19 points), and high (20 or more points) risk
groups. In a similar way, the simpliﬁed ERICVA score was
divided into low (0 points), medium (1 point), and high (2 or
more points) risk, resulting in a similar KaplaneMeier curve
for both scales (Fig. 3).
Validation and comparison between different scales in
both subsamples
After applying the Finnvasc, PREVENT III, ERICVA, and
ERICVA-Simpliﬁed scales to the development and validationExp(B) (hazard ratio) CI 95.0% for Exp(B)
Lower Upper
.006 1.667 1.157 2.403
.049 1.571 0.995 2.479
.048 1.296 0.991 1.694
.003 2.507 1.372 4.581
.001 1.758 1.263 2.448
.001 3.253 2.297 4.607
.001 2.490 1.625 3.814
.001 2.325 1.732 3.121
.001 1.748 1.297 2.355
.048 1.349 1.003 1.814
.001 2.376 1.697 3.328
Figure 2. KaplaneMeier curves of the development score subsample for the ERICVA scale, stratiﬁed by risk levels.
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were constructed to assess the predictive value of each
scale for AFS at 1 year (Fig. 4). The AUC of the ERICVA scale,
in its two versions, was signiﬁcantly higher than the PRE-
VENT III and Finnvasc scores; in the validation subsample,
there were no signiﬁcant differences between the AUC of
ERICVA (both versions) and PREVENT III scales, but the AUC
was signiﬁcantly higher compared with Finnvasc (Table 7).DISCUSSION
The population studied in this work represents a wide
spectrum of revascularization techniques for CLI. The ﬁnd-
ings are in line with most other trials regarding this subject.1
Moreover, within the homogeneity of the development and
validation samples, there were small differences that show
the evolution of vascular surgery in recent years, and so
more distal endovascular procedures were performed in
patients in worse clinical condition. Also, in terms of thevariables included in the model, some were included that
have not traditionally been associated with worse outcomes
in patients with critical ischaemia. The presence of a high
neutrophil/lymphocyte ratio reafﬁrms it once again as a
marker of poor prognosis,14 but revascularization in cancer
patients has barely been referenced so far in the literature.
The ERICVA risk model is the ﬁrst to be developed in
Spain, and the second in Europe in the context of revas-
cularization in patients with CLI. In the environment where
it has been developed, it allows the objective identiﬁcation
of patients at high risk of death and/or major amputation 1
year after the intervention. Its greatest potential is that it
can be helpful in making the decision of whether or not to
perform revascularization in a particular patient, and it
provides some objectivity when determining surgical risks
involved in these procedures. It also allows estimation of
the risk proﬁle of patients seen in a given centre, which is
useful for making benchmark comparisons.
Figure 3. KaplaneMeier curves of the development score subsample for the ERICVA-Simpliﬁed scale, stratiﬁed by risk levels.
Figure 4. Receiver operator curves for PREVENT III, Finnvasc, ERICVA and ERICVA-Simpliﬁed scales applied to the development and
validation subsamples.
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Table 7. Area under the curve of the different scales in the development and validation subsamples (*, p < 0.05).
Scales Area under the curve (C statistic) C Statistic standard error p CI (95%)
ERICVA scale (development) 0.737 0.024 <.001* 0.690e0.784
ERICVA scale (validation) 0.708 0.054 <.001* 0.599e0.812
ERICVA-Simpliﬁed scale (development) 0.684 0.026 <.001* 0.634e0.734
ERICVA-Simpliﬁed scale (validation) 0.763 0.050 <.001* 0.666e0.860
PREVENT III (development) 0.618 0.026 <.001* 0.566e0.670
PREVENT III (validation) 0.707 0.054 <.001* 0.601e0.813
Finnvasc (development) 0.579 0.027 .003* 0.527e0.631
Finnvasc (validation) 0.541 0.058 .478 0.428e0.654
Comparison between ROC curves (De Long method)
Development subsample Validation subsample
c2 p c2 p
ERICVA versus PREVENT III 7.0295 .0080* 0.0005 .9830
ERICVA versus Finnvasc 14.4622 <.0001* 4.5805 .0323*
ERICVA-Simpliﬁed versus PREVENT III 4.0199 .0450* 0.6289 .4277
ERICVA-Simpliﬁed versus Finnvasc 10.2740 .0013* 9.7975 .0017*
ERICVA-Simpliﬁed versus ERICVA 0.6084 .4354 0.6489 .4205
98 J.A. Brizuela Sanz et al.One of the main contributions of this model is the ease of
use because of its easier summation. Furthermore, items
are easily gathered, since they are drawn from the clinical
history, physical examination, vascular examination, and
blood tests that are performed routinely on patients treated
for CLI. It is very intuitive to use: the higher the score, the
higher the rate of death and/or major amputation at 1 year.
The ERICVA-Simpliﬁed version is a more simple application
which maintains the same level of reliability and that can be
performed at the patient’s bedside.
One of the questions posed by risk models is their pre-
dictive capacity away from the local population environ-
ment where they have been developed. In this study it was
observed that the Finnvasc scale revealed a low predictive
ability, while the PREVENT III scale showed a relatively good
performance in the development sample. As for the ERICVA
model, which was useful locally, its usefulness in other lo-
cations has yet to be proven.
Another of the difﬁculties that risk models face is their
validity over time. It is known that over the years, surgical
indications change and new techniques emerge, and the
clinical proﬁles of the intervened population are not the
same; it is questionable, therefore, whether the validity of
the risk model persists after such changes. This is why
updating databases and recalibration of the risk scales is
fundamental.
There are several characteristics that must be observed
when evaluating a predictive model (Table 8). First is the
target variable. In the Finnvasc, PREVENT III, and ERICVATable 8. Comparison of different risk models.
Scales Primary endpoint Time of event Veriﬁ
PREVENT III Amputation free survival 1 year Infra
Finnvasc Amputation free survival 30 days (1 year) Infra
ERICVA Amputation free survival 1 year All in
endo
infra
BASIL Patient survival 2 years Infra
CRAB Major morbidity-free survival 30 days Infrascales, this target variable was AFS, whereas in the CRAB
scale it was mortality and major morbidity, and in the BASIL
model the target variable was survival at 2 years. It is
believed that, unlike the CRAB and BASIL models, it is
important to consider the risk of amputation in assessing
the outcome of revascularization for CLI. The time when the
unfavourable event happens is also important and can be
evaluated in the immediate pre-operative period (CRAB
scales and Finnvasc), at 1 year (scales Finnvasc, PREVENT III,
and ERICVA) or at 2 years (BASIL).5e11
Furthermore, the origin of the population from which the
models are generated affect their applicability. The scales
that have been developed from clinical trials (BASIL, PRE-
VENT III) are likely to constitute a different picture from real
clinical practice. In contrast, the Finnvasc, CRAB, and ERICVA
scales have been developed from clinical records based on
actual clinical practice. Moreover, the ERICVA risk model is
the only one so far that has been developed from a pop-
ulation that has received both conventional and endovas-
cular treatmentdsupra- and infrainguinaldwhile other
models have focused only on open infrainguinal conven-
tional surgery (although the PREVENT III and Finnvasc scales
have been externally validated for infrainguinal endovas-
cular surgery).5e11
The developed model is not without limitations, two of
which are the single institution and the retrospective na-
ture of the study. It is therefore believed that the fate of
the ERICVA scale depends on its future multicentre and
international implementation in order to obtain externaled interventions Origin of population
inguinal bypass USA Clinical Trial Multicentre
inguinal bypass Finland Registry Multicentre
terventions (conventional/
vascular) (supra- and/or
inguinal)
Spanish Registry single centre
inguinal PTA and/or bypass European Clinical Trial Multicentre
inguinal bypass USA Registry Multicentre
Design of a New Risk Score in Critical Limb Ischaemia 99validation that can make a more universally applicable
model.
CONCLUSIONS
The developed ERICVA risk model has an acceptable pre-
dictive value of AFS 1 year after revascularization of CLI, and
this capacity was slightly higher than the PREVENT III scale
and clearly superior to the Finnvasc model in our clinical
setting.
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